← Back to Events
Tier 1 Global Networking: High IMMUNOLOGY CONCLUDED
EULAR 2026 — Not specified, London, UK
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026. Our organising committee have created a .
5,000+ Attendees
5 Presentations
3 Companies
2 Drugs
Presentation data updated Jun 5, 2026, 8:41 AM UTC
Nova Event Impact Score
50 /100
- Media coverage 10/20
- Speaker quality 20/20
- Pipeline relevance 1/20
- Historical influence 13/20
- Company participation 6/20
Key Takeaways
Key Themes
immunologyEuropean League Against Rheumatism (EULAR)Pipeline announcementsPartnership deals
Key Companies
AmgenUCBNovartis
Key Drugs
inebilizumabbimekizumab
Key Markets
Europe
Key Opportunities
Partnership dealsLicensing discussionsVendor selection
Investors & analysts
Full Schedule
ORAL
ORAL Jun 3
OP0185
Treatment retention and clinical remission in 787 real-world patients with psoriatic arthritis treated with bimekizumab
ORAL Jun 3
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio in complex high unmet need diseases
ORAL
Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) in immunoglobulin G4-related disease (IgG4-RD): open-label extension data
ORAL
Novartis data in polymyalgia rheumatica: efficacy and safety of novel therapy